These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. Oncolytic herpesvirus expressing PD-L1 BiTE for cancer therapy: exploiting tumor immune suppression as an opportunity for targeted immunotherapy. Khalique H; Baugh R; Dyer A; Scott EM; Frost S; Larkin S; Lei-Rossmann J; Seymour LW J Immunother Cancer; 2021 Mar; 9(4):. PubMed ID: 33820820 [TBL] [Abstract][Full Text] [Related]
5. Immune response is an important aspect of the antitumor effect produced by a CD40L-encoding oncolytic adenovirus. Diaconu I; Cerullo V; Hirvinen ML; Escutenaire S; Ugolini M; Pesonen SK; Bramante S; Parviainen S; Kanerva A; Loskog AS; Eliopoulos AG; Pesonen S; Hemminki A Cancer Res; 2012 May; 72(9):2327-38. PubMed ID: 22396493 [TBL] [Abstract][Full Text] [Related]
6. Adjuvant Therapy with Oncolytic Adenovirus Delta-24-RGDOX After Intratumoral Adoptive T-cell Therapy Promotes Antigen Spread to Sustain Systemic Antitumor Immunity. Jiang H; Shin DH; Yi Y; Fan X; Gumin J; He J; Gillard AG; Lang FF; Gomez-Manzano C; Fueyo J Cancer Res Commun; 2023 Jun; 3(6):1118-1131. PubMed ID: 37379361 [TBL] [Abstract][Full Text] [Related]
7. An engineered oncolytic virus expressing PD-L1 inhibitors activates tumor neoantigen-specific T cell responses. Wang G; Kang X; Chen KS; Jehng T; Jones L; Chen J; Huang XF; Chen SY Nat Commun; 2020 Mar; 11(1):1395. PubMed ID: 32170083 [TBL] [Abstract][Full Text] [Related]
8. Hemagglutinating virus of Japan-envelope containing programmed cell death-ligand 1 siRNA inhibits immunosuppressive activities and elicits antitumor immune responses in glioma. Sugii N; Matsuda M; Okumura G; Shibuya A; Ishikawa E; Kaneda Y; Matsumura A Cancer Sci; 2021 Jan; 112(1):81-90. PubMed ID: 33155337 [TBL] [Abstract][Full Text] [Related]
9. The oncolytic virus VT09X optimizes immune checkpoint therapy in low immunogenic melanoma. Zhu W; Lv J; Xie X; Tian C; Liu J; Zhou H; Sun C; Li J; Hu Z; Li X Immunol Lett; 2022 Jan; 241():15-22. PubMed ID: 34774916 [TBL] [Abstract][Full Text] [Related]
10. In situ delivery of iPSC-derived dendritic cells with local radiotherapy generates systemic antitumor immunity and potentiates PD-L1 blockade in preclinical poorly immunogenic tumor models. Oba T; Makino K; Kajihara R; Yokoi T; Araki R; Abe M; Minderman H; Chang AE; Odunsi K; Ito F J Immunother Cancer; 2021 May; 9(5):. PubMed ID: 34049930 [TBL] [Abstract][Full Text] [Related]
12. Expression of tumor antigens within an oncolytic virus enhances the anti-tumor T cell response. Webb MJ; Sangsuwannukul T; van Vloten J; Evgin L; Kendall B; Tonne J; Thompson J; Metko M; Moore M; Chiriboga Yerovi MP; Olin M; Borgatti A; McNiven M; Monga SPS; Borad MJ; Melcher A; Roberts LR; Vile R Nat Commun; 2024 Jun; 15(1):5442. PubMed ID: 38937436 [TBL] [Abstract][Full Text] [Related]
13. Armed Oncolytic Adenovirus-Expressing PD-L1 Mini-Body Enhances Antitumor Effects of Chimeric Antigen Receptor T Cells in Solid Tumors. Tanoue K; Rosewell Shaw A; Watanabe N; Porter C; Rana B; Gottschalk S; Brenner M; Suzuki M Cancer Res; 2017 Apr; 77(8):2040-2051. PubMed ID: 28235763 [TBL] [Abstract][Full Text] [Related]
14. Novel oncolytic adenovirus expressing enhanced cross-hybrid IgGA Fc PD-L1 inhibitor activates multiple immune effector populations leading to enhanced tumor killing in vitro, in vivo and with patient-derived tumor organoids. Hamdan F; Ylösmäki E; Chiaro J; Giannoula Y; Long M; Fusciello M; Feola S; Martins B; Feodoroff M; Antignani G; Russo S; Kari O; Lee M; Järvinen P; Nisen H; Kreutzman A; Leusen J; Mustjoki S; McWilliams TG; Grönholm M; Cerullo V J Immunother Cancer; 2021 Aug; 9(8):. PubMed ID: 34362830 [TBL] [Abstract][Full Text] [Related]
15. Intratumoral Delivery of a PD-1-Blocking scFv Encoded in Oncolytic HSV-1 Promotes Antitumor Immunity and Synergizes with TIGIT Blockade. Lin C; Ren W; Luo Y; Li S; Chang Y; Li L; Xiong D; Huang X; Xu Z; Yu Z; Wang Y; Zhang J; Huang C; Xia N Cancer Immunol Res; 2020 May; 8(5):632-647. PubMed ID: 32127389 [TBL] [Abstract][Full Text] [Related]
17. Enhanced antitumor effect of oncolytic adenovirus expressing interleukin-12 and B7-1 in an immunocompetent murine model. Lee YS; Kim JH; Choi KJ; Choi IK; Kim H; Cho S; Cho BC; Yun CO Clin Cancer Res; 2006 Oct; 12(19):5859-68. PubMed ID: 17020994 [TBL] [Abstract][Full Text] [Related]
18. An oncolytic vaccinia virus armed with anti-human-PD-1 antibody and anti-human-4-1BB antibody double genes for cancer-targeted therapy. Shi Z; Liu B; Huang C; Xie W; Cen Y; Chen L; Liang M Biochem Biophys Res Commun; 2021 Jun; 559():176-182. PubMed ID: 33945995 [TBL] [Abstract][Full Text] [Related]
19. Novel Oncolytic Herpes Simplex Virus 1 VC2 Promotes Long-Lasting, Systemic Anti-melanoma Tumor Immune Responses and Increased Survival in an Immunocompetent B16F10-Derived Mouse Melanoma Model. Uche IK; Fowlkes N; Vu L; Watanabe T; Carossino M; Nabi R; Del Piero F; Rudd JS; Kousoulas KG; Rider PJF J Virol; 2021 Jan; 95(3):. PubMed ID: 33177208 [TBL] [Abstract][Full Text] [Related]
20. Concurrent delivery of GM-CSF and B7-1 using an oncolytic adenovirus elicits potent antitumor effect. Choi KJ; Kim JH; Lee YS; Kim J; Suh BS; Kim H; Cho S; Sohn JH; Kim GE; Yun CO Gene Ther; 2006 Jul; 13(13):1010-20. PubMed ID: 16525479 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]